Genetic Technologies (GENE) has released an update.
Genetic Technologies has announced a registered direct offering set to raise around US$2 million by selling American Depositary Shares and concurrent private placement of Warrants. The proceeds are intended to boost revenue through sales and marketing initiatives, including the launch of a digital strategy and expansion of the company’s genetic testing product line. The offering, expected to close on April 22, 2024, is facilitated by H.C. Wainwright & Co., with no shareholder approval required following a recent EGM.
For further insights into GENE stock, check out TipRanks’ Stock Analysis page.
